GlassScriptPhysician profile
Steven A Shanbom
NPI 1265433742
$5,810.69
in general payments reported to CMS, 2019-2025
26 companies · $430 in 2025
The $430 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $868 · 2020: $366 · 2021: $1,152 · 2022: $641 · 2023: $1,818 · 2024: $535 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,783 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,783.28 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $1,116.79 | 2019-2025 | Tearcare System, Omni Surgical System, Sion Surgical Instrument |
| Alcon Vision LLC | $867.11 | 2019-2025 | Clareon, Rocklatan, Tryptyr |
| Sun Pharmaceutical Industries INC. | $500.22 | 2019-2025 | Cequa |
| Carl Zeiss Meditec, INC. | $464.71 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $430.01 | 2019-2024 | Tecnis Simplicity, Tecnis Iol, Catalys System |
| Abbvie INC. | $353.21 | 2022-2023 | Durysta, Xen Glaucoma Treatment System |
| Glaukos Corporation | $217.34 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $207.58 | 2019-2021 | |
| Allergan, INC. | $197.65 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $190.57 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Novartis Pharmaceuticals Corporation | $186.08 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $164.17 | 2019-2021 | |
| Ocular Therapeutix, INC. | $151.92 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $148.91 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $117.93 | 2023-2024 | Tyrvaya |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $95.12 | 2019 | |
| Harrow Eye, LLC | $63.63 | 2025 | Triesence, Vevye |
| Rayner Intraocular Lenses Limited | $54.25 | 2022-2023 | Omidria, Rayone Emv, Rayone Aspheric |
| Biotissue Holdings INC. | $52.67 | 2022-2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $45.21 | 2019-2020 | |
| New World Medical,INC. | $45.09 | 2022-2024 | Ahmed Glaucoma Valve, Streamline, Clearpath |
| Rxsight INC | $43.60 | 2023-2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Carl Zeiss Meditec USA, INC. | $42.07 | 2021 | |
| Eyevance Pharmaceuticals LLC | $27.09 | 2020 | |
| Galderma Laboratories, L.P. | $19.20 | 2021 | |
| Lensar, INC. | $8.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Shanbom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.